-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4847 mRNA-Laden Lipid-Nanoparticles-Enabled CD19 CAR-T Cells Engineering for the Eradication of Leukemic Cells

Program: Oral and Poster Abstracts
Session: 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Translational Research
Monday, December 9, 2024, 6:00 PM-8:00 PM

Zhaozhao Chen, Doctor1*, Anqi Ren, Master1,2*, Jinhui Shu, Master3*, Yingying Li4,5*, Hekuan Huang, Bachelor2,3*, Yu Hu3,4* and Heng Mei, Doctor1*

1Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, 中国, China
2Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China
4Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5Hubei Clinical and Research Centre of Thrombosis and Haemostasis, Wuhan, China

Objective: With the continuous approval and commercialization of chimeric antigen receptor T cell (CAR-T) products worldwide, CAR-T therapy has emerged as a promising approach for treating malignant tumors. However, these viral-vectors-based CAR-T cells are of close-to-prohibitive manufacturing costs, and the risks of insertional mutagenesis and secondary tumor formation. Messenger RNA (mRNA) delivery through lipid nanoparticles (LNPs) presents a novel strategy to engineer CAR-T cells, potentially reducing production costs and improving treatment-related safety, while maintaining anti-tumor activity. In this study, we developed an innovative approach for engineering CD19 CAR-T cells using mRNA-LNPs, and the anti-leukemic cells effects of CAR-T cells were validated in both in vitro and in vivo settings.

Methods: With microfluidic technology, the mRNA encoding the full humanized anti-CD19 CAR was encapsulated into mRNA-lipid nanoparticles (mRNA-LNPs) and subsequently characterized. We optimized the LNP-based transfection protocol to efficiently deliver mRNA encoding CAR constructs into T cells. The engineered CAR-T cells were then evaluated for their ability to eradicate tumor cells in vitro and in vivo. We evaluated cytokine secretion and cytotoxic activity through co-culture with target cells (Raji cells) in vitro. Furthermore, we introduced mRNA-LNP-engineered CD19 CAR-T cells into NOD-scid-IL2Rγnull (NSG) mice engrafted with Raji-luc cells, and dynamically monitored changes in tumor burden using in vivo bioluminescence imaging.

Results: Our results demonstrate that the size of the mRNA-LNPs is approximately 100 nm, and possess a negative charge, and maintain stability in PBS for 7 days. mRNA-LNPs efficiently transfect T cells, leading to high expression levels of CAR molecules (>70%), and the expression was maintained in vitro for 16 days. Moreover, CAR-T cells engineered using mRNA-LNPs exhibit potent cytotoxicity against tumor cells in vitro, as evidenced by increased tumor cell killing compared to traditional CAR-T cells. Furthermore, in a xenograft mouse model of Raji cells, administration of mRNA-LNP-enabled CAR-T cells resulted in significant tumor regression and prolonged survival period to more than 60 days of treated animals.

Conclusion: This study highlights the potential of mRNA-LNP transfection for CAR-T cell therapy in eradicating tumor cells. The innovative approach described here offers a promising strategy for improving the clinical outcomes of CAR-T cell therapy and advancing the field of cancer immunotherapy.

Disclosures: No relevant conflicts of interest to declare.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH